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Despite improved treatment and access to care, adolescent AIDS deaths are decreasing 
more slowly than in any other age group. There is lack of longitudinal data around 
adolescent adherence and the dynamics of viraemia over time. We aimed to describe 
patterns of detectable viral load in a cohort of adolescents attending an antiretroviral 
clinic in Cape Town, South Africa. 
 
Methods 
We conducted a retrospective cohort study of all patients on ART aged 10-19 years. 
Participants were included if they underwent at least two HIV viral load (VL) 
measurements and attended the Groote Schuur Hospital HIV Clinic for at least 24 months 
between 2002 and 2016. The primary outcome was two consecutive VL >100 copies/ml, 
in line with the lower limit of detection of assays in use over the follow-up period. 
 
Results 
Of 482 screened subjects, 327 met inclusion criteria. Most subjects were vertically 
infected (n= 314; 96%), and 170 (52%) were male. 
Overall, 203 episodes of confirmed detectable VL involving 159 (49% [95% CI 43%–54%]) 
subjects were experienced during the follow-up period. A total of 111 (34%) subjects 
never experienced detectable VL, while 16 (5%) never suppressed throughout the follow-
up period. Median age at first detectable VL was 14 (IQR 11-16) years. Of the 159 subjects 
who experienced detectable VL, 102 (64%) re-suppressed, of which 38 (37%) had a 
subsequent detectable VL.  
Six subjects had genotyped resistance to protease inhibitors. Four of these never 
suppressed, while two suppressed on salvage regimens. 
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Total follow-up time was 1723 person years (PY), of which 880 (51%) were contributed by 
the 159 subjects who experienced detectable VL. Overall time with detectable VL was 
370 PY. This comprised 22% of total follow-up time, but 42% of the follow-up time 
contributed by those who experienced detectable VL. 
 
The rate of detectable VL was 11.8 (95% CI 10.3–13.5) episodes per 100 PY. The risk 
increased by 24% for each year of increasing age (RR 1.24 [95% CI 1.17-1.31]; p<0.0001). 
Neither prevalence, duration nor rate of detectable VL was influenced by gender. 
 
Conclusion 
Detectable VL was seen in nearly half of adolescents, with the rate increasing with age. 
Viraemia was not a static process, and adolescents moved in and out of this state as 
adolescence progressed. Further study is warranted to correlate these findings with risks 








I wish to acknowledge the attentive support and mentoring received from my supervisor, 
Dr. Rudzani Muloiwa. He has consistently made himself available to “bounce ideas 
around” – from major conceptual issues to finer points of table formatting. Thank you for 
backing me up on this, and for always making time. 
I am also grateful for the input received from my co-supervisor, Prof. Sipho Dlamini, 
whose deep understanding of HIV strengthened both the content and form of this 
dissertation. 
I wish to thank my colleagues in the GSH Paediatric and Adolescent HIV Service, who 
provided a sounding board for ideas, and generously helped with my clinical workload 
while I completed this dissertation. 
Finally, I would like to acknowledge the patients who comprise the subjects of this study. 
Their resilience is an inspiration to me. I hope that this work can play its small part in the 








TABLE OF CONTENTS VI 
LIST OF ABBREVIATIONS IX 
LIST OF FIGURES X 
LIST OF TABLES XI 
APPENDICES XII 
1 INTRODUCTION 1 
1.1 Background 1 
1.2 Context 2 
1.3 Aim 3 
1.4 Study Design 3 
1.5 Rationale 3 
1.6 Summary 4 
2 LITERATURE REVIEW 5 
2.1 Introduction 5 
2.2 Methods 5 
2.3 The Adolescent HIV Epidemic 6 
2.4 Measures of Adherence 6 
2.5 The HIV Viral Load 8 
 vii 
2.6 Virological resistance 9 
2.7 Epidemiology of Detectable Viral Load in Adolescents 10 
2.7.1 Prevalence 10 
2.7.2 Retention in care 13 
2.7.3 Incidence 13 
2.7.4 Duration of detectable VL 14 
2.7.5 Viral rebound and re-suppression 14 
2.8 Factors associated with detectable VL 15 
2.8.1 Age 16 
2.8.2 Gender 17 
2.8.3 Time on ART 18 
2.8.4 Age at ART initiation 19 
2.9 Conclusion 19 
3 METHODS 21 
3.1 Introduction 21 
3.2 Aims 21 
3.3 Objectives 21 
3.4 Study Design 22 
3.4.1 Study Population 22 
3.4.2 Outcomes of Interest 23 
3.5 Study procedure 23 
3.6 Patient safety and confidentiality 24 
3.7 Data management and statistical analysis 24 
3.8 Ethical considerations 25 
4 RESULTS 26 
4.1 Inclusions 26 
4.2 Baseline characteristic of study population 26 
4.3 Prevalence of detectable viral load (VL) 28 
 viii 
4.4 Re-suppression and viral rebound 29 
4.5 Incidence of detectable viral load 32 
4.6 Time spent with detectable VL 34 
4.7 Loss to Follow-up 35 
4.8 Mortality 35 
5 DISCUSSION 37 
5.1 Introduction 37 
5.2 Prevalence 37 
5.2.1 Subjects with no detectable VL 37 
5.2.2 Subjects with all detectable VL 38 
5.3 Incidence 39 
5.4 Duration 39 
5.5 Re-suppression and viral rebound 40 
5.6 Associations 41 
5.6.1 Age 42 
5.6.2 Sex 42 
5.6.3 Time on ART 42 
5.6.4 Age at ART 43 
5.6.5 Calendar year 43 
5.7 Mortality 44 
6 CONCLUSIONS 45 
6.1 Limitations 45 
6.2 Recommendations 46 
6.2.1 Clinical recommendations 46 




LIST OF ABBREVIATIONS 
 
 
AIDS  Acquired Immune Deficiency Syndrome 
 
ART  Antiretroviral Therapy 
 
ARVs  Antiretrovirals 
 
HIV  Human Immunodeficiency Virus 
 
IQR  Inter-Quartile Range 
 
LMIC  Low and Middle-Income Country 
 
NNRTI  Non-Nucleoside Reverse Transcriptase Inhibitor 
 
PI  Protease Inhibitor 
 
PY  Person Years 
 






LIST OF FIGURES 
 
Figure 4.1 Number of adolescents seen per calendar year.    26 
 
Figure 4.2 Re-suppression and viral rebound      30 
 
Figure 4.3 Rate of detectable VL by age and sex     33  
 








LIST OF TABLES 
 
Table 4.1 Baseline characteristics of HIV infected adolescents 
 
27 
Table 4.2 Prevalence of detectable viral load 29 
 















Appendix 1. Human Research Ethics Committee Approval    59 
 
Appendix 2. Copy of Case Report Form      60 
 







Since 2005, global deaths from AIDS have fallen by almost 40% across all age groups 
except adolescents. In this group, despite the massive upscaling of antiretroviral therapy 
(ART), overall AIDS-related deaths are decreasing at a much slower rate, and in older 
adolescents still show an increasing trend.(1-3) Globally, AIDS is among the top ten 
leading causes of death for adolescents.(3, 4) 
 
Accounting for this relatively slow decline in adolescent mortality is challenging because 
of a lack of adolescent-specific data. HIV data are often presented as either children 
(younger than 15 years of age) or adults (aged 15 years and above). Disaggregated 
adolescent specific data are largely unavailable. Where estimates of HIV prevalence 
among adolescents  are available, these tend not to distinguish between vertical and 
horizontal transmission.(5) The scale of the epidemic is such that of an estimated 1,2 
billion adolescents alive in 2016, 2.1 million were living with HIV.(6)  
 
Among vertically-infected children, models predict that without ART, a child who acquires 
HIV during pregnancy or birth will die at about one year of age. Those who are infected 
via breast-feeding (around half of all vertically infected children) are expected to survive 
for an average of fourteen years.(5) Without diagnosis and treatment, vertically infected 
children and adolescents are at high risk of mortality.(5) Unfortunately, ART coverage 
remains low in children. Of the 2.1 million HIV-infected children under 15 years 
worldwide, only 43% were receiving ART in 2017, meaning that most vertically-infected 
children are not on treatment as they enter adolescence.(6)  
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Among horizontally-infected adolescents, HIV testing is low, and as a result, treatment 
may be delayed until they have very advanced disease.(1) It thus seems likely that in Sub-
Saharan Africa, where almost 80% of HIV-infected adolescents live, lack of diagnosis and 
access to care contribute to mortality.(1, 7) 
 
However, even among adolescents who do access treatment, outcomes are poorer than 
those of children and adults on ART.(8) In general, adherence to medication in chronic 
disease tends to drop off in adolescence, causing a corresponding increase in morbidity 
and mortality.(9) The consequences of ongoing detectable HIV viraemia include immune 
destruction, disease progression with higher risk of mortality, and greater risk of onward 
transmission of HIV.(9-13) In comparison to adults, adolescents in southern Africa have 
been found to be less adherent to ART, and have displayed lower rates of virological 
suppression and immunological recovery as well a higher rate of virological rebound after 
initial suppression.(8, 14) The association between adherence to ART and viral 
suppression has been well-documented across age-groups.(8) It is estimated that for 
successful clinical, immunological and virological outcomes, ART adherence needs to be 
at least 95%.(9) There is evidence that world-wide, adolescents struggle to meet these 




In Sub-Saharan Africa, where more than three quarters of the world’s HIV-infected 
adolescents live, most facilities that treat adolescents do not have adolescent-specific 
services. (7, 17) Although the South African Department of Health has prioritised 
programming for adolescents and youth, many gaps remain.(18)  
 
In contrast, the Groote Schuur Hospital Adolescent Clinic has had a dedicated adolescent 
service since 2005. The adolescent clinic grew out of one of the first paediatric HIV clinics 
in South Africa, which began prescribing ART to children in 2002, a full two years before 
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the national roll-out. Many of the adolescents attending the clinic were among the first 
children in the public sector to receive ART. There are thus detailed medical records 
pertaining to these children since 2002. Structured clerking notes ensure that 
psychosocial information such as the identity of the caregiver or scholastic failure is 
regularly documented. While most children attending this clinic are vertically infected 
with HIV, a small proportion of adolescents enter the service following horizontal 
infection. The clinical team has been relatively stable since the inception of the clinic. 
Each patient sees the same doctor and counsellor at each visit. In the few instances in 
which staff changes have taken place, each patient was handed over to a specific 
caregiver in order to maintain continuity of care. A modest transport subsidy was 
available to those in need for the most of the clinic’s history. The excellent quality of 
patient records and the long period of follow-up mean that this site offers an unusual 





Our study aimed to determine the burden of detectable viral load in a cohort of HIV 
infected adolescents seen at the Groote Schuur Hospital Adolescent HIV Clinic.  
 
1.4 Study Design 
 
A retrospective cohort study using medical records was performed. The period under 




Through this research, we hope to contribute to the understanding of virological 
outcomes in adolescents on ART. More specifically, we hope to address what we perceive 
to be a gap in the literature, namely the dynamics of viraemia – and, by extension - 
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adherence over time in a low and middle-income country setting (LMIC). We hope that 
the findings of the study can be used to identify adolescents at high risk of unsuppressed 
viral load and to offer extra assistance. Moreover, it is hoped that the data here 
generated will be more broadly relevant, and could be used to guide policy towards 




The subsequent chapters will take the following format: 
Chapter 2: Literature Review 
This chapter reviews published literature on unsuppressed viral load in adolescents on 
ART. Epidemiological data concerning adolescent HIV are summarized, and conceptual 
difficulties with measuring adherence to ART discussed. Throughout, the lack of 
longitudinal data in the field will be highlighted. 
Chapter 3: Methodology 
This chapter describes the research design, methods and procedures, including how data 
were handled and analysed as well as the handling of ethical issues and study approval. 
Chapter 4: Results 
In which study findings are reported. 
Chapter 5: Discussion 
In which study findings are interpreted, and reviewed in the context of existing literature 
in the field. 
Chapter 6: Conclusion 
The contribution of this study to the literature is summarised, and its limitations noted. 
Recommendations are made for further study, and for the application of these findings to 
policy or clinical work.  
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AIDS-related deaths in adolescents are decreasing much more slowly than in all other 
age-groups.(3, 6) Despite improved treatment and access to care, HIV/AIDS is listed as 
one of the top ten leading causes of death in adolescents globally.(2-4) This can be 
partially attributed to a lack of diagnosis and treatment, but even among adolescents 
who do access care, outcomes are worse than in other age-groups.(5, 8, 19) This is 
thought to result from poor adherence to antiretroviral therapy (ART).(9, 15) 
 
This chapter will review the literature around the topic of adolescent adherence to ART, 
with a focus on viral load outcomes. Measures of adherence will be discussed, as well as 
the merits and shortfalls of using the HIV viral load (VL) as a proxy for adherence and an 
outcome variable. The epidemiology of detectable viral load in adolescents will be 




An electronic search for English-language articles was performed using Pubmed without 
restrictions. The initial search was performed in January 2017, and was repeated a 
number of times with the latest search conducted on 8 February 2018. A sensitive search 
strategy was adopted using various forms of combinations of text and MeSH terms of the 
following words: ‘adolescent’, ‘HIV’, ‘adherence’, ‘viral load’, ‘antiretroviral therapy’, 
‘prevalence’, ‘incidence’ and ‘duration’. A total of 179 eligible studies were found, of 




2.3 The Adolescent HIV Epidemic 
 
The adolescent HIV epidemic is comprised of a mix of vertically-infected children who age 
into adolescence, and adolescents with new, horizontal infections.(2) In recent years 
there has been an increased focus on adolescents, although most data reporting at 
country level still does not provide disaggregated data on this group.(6) Moreover, 
adolescent data often does not distinguish between vertical and horizontal 
transmission.(5)  
 
Of the 1.2 billion adolescents alive worldwide in 2017, 2.1 million were estimated to be 
living with HIV. This indicates an increase of 30% since the 2005 estimates.(6) In 2015, 
80% of the world’s HIV-infected adolescents lived in Sub-Saharan Africa, however 32% of 
new infections among 15-19 year olds occurred outside of this region. This suggests that 
adolescent HIV is indeed a global issue.(7) South Africa has the largest number of people 
living with HIV in the world, and in 2012 carried 20% of the global adolescent HIV 
burden.(2) In 2016 there were 370 000 adolescents living with HIV in South Africa, with 
6200 adolescent AIDS-related deaths.(20) 
 
Overall, AIDS-related deaths in adolescents have declined by a small amount each year 
since 2012, largely due to decreasing mortality in younger adolescents aged 10-14 years. 
In contrast, older adolescents aged 15 – 19 years are the only age group in which AIDS 
deaths have continued to rise.(2, 3) It is thought that this mortality is mainly made up of 
vertically-infected adolescents as horizontally-infected adolescents would have had 
relatively recent infections, though the evidence to support this is lacking.(2) 
 
2.4 Measures of Adherence 
 
Adherence to ART is notoriously difficult to measure, particularly as there is no gold 
standard.(19, 21-23) The most common means of monitoring adherence is by self-report. 
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This is vulnerable to over-reporting, as has been illustrated in trials comparing self-
reporting to more objective measures such as electronic adherence monitoring devices or 
pharmacy refill.(22, 24-26)  
 
As there are different patterns of non-adherence, self-report questionnaires may not 
screen for all patterns.(27) This is illustrated in the way that self-reported adherence 
estimates vary depending on the particular questions asked.(28) Additional challenges 
arise in adolescence, where there may be significant discordance between caregiver and 
youth estimates of adherence. The reliability of the estimate depends in part on the age 
of the adolescent. The caregiver report may be more useful in younger adolescents, while 
self-report may be more appropriate in an older age group.(21) 
 
There is conflicting evidence on the usefulness of pill-counts, which can be confounded 
by pill-dumping (discarding pills in order to give the impression of better adherence). 
However, pharmacy refill data has been found to be a good predictor of virological failure 
across multiple studies.(22, 25) 
 
There is general consensus that the most accurate means of monitoring antiretroviral 
adherence is through serial measurements of plasma HIV viral load (VL).(21, 22, 25) A 
high viral load is not synonymous with poor adherence, as it may result from virological 
resistance or more rarely, drug interactions or malabsorption. The interaction between 
rifampicin-based therapy for tuberculosis and protease inhibitors in particular has been 
associated with the development of resistance mutations.(9) Despite this, the association 
between adherence to ART and viral suppression has been well described in all age-
groups.(9) In the context of effective ART, the HIV VL can be seen as both the outcome of 
adherence, and a sensitive means by which to monitor adherence. An undetectable HIV 
VL would indicate successful treatment, from which good adherence can be inferred.(10)  
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2.5 The HIV Viral Load 
 
The HIV viral load is used as a “pivotal outcome variable” in a wide variety of studies of 
HIV infection, including drug trials, adherence studies and observational cohorts.(29) In 
addition to being a proxy marker of adherence, VL is frequently employed as a surrogate 
for disease progression.(10, 30) Evidence shows that HIV viraemia is associated with 
clinical deterioration independent of CD4 count, and that it predicts the development of 
resistance mutations which necessitate a change of treatment.(10) After 6 months on 
treatment, VL >400 copies/ml has been found to be a risk factor for death in vertically-
infected children and adolescents.(11) The World Health Organization (WHO) 
recommends that VL be used as a gold standard for monitoring HIV treatment in all 
patients.(31) 
 
Within a research context, single measures of VL are frequently used as an outcome 
variable (e.g. closest VL to month 12 after start of ART). Rose et al compared methods of 
analysing HIV VL data using single vs. repeat measures of VL, and concluded that repeat 
measurements provided more precision.(29)  
 
Different assays also have different levels of detection, the limit of which has dropped 
over time from 500 copies/ml in 2000, to around 20 copies/ml since 2009.(32, 33) This 
may cause confusion, as the same level of VL may be classified as “detectable” or 
“undetectable” depending on the limit of detection, which varies according to time, 
context and assay used.(32) 
 
The concept of treatment failure is based on confirming a detectable viral load.(10) 
Currently, the WHO and the South African Department of Health define treatment failure 
as consecutive viral loads of >1000 copies/ ml.(34, 35) However, there is evidence that 
even low level viraemia is associated with subsequent treatment failure and the 
development of resistance mutations, necessitating a switch to an alternative 
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regimen.(36-38) These findings have been well-established in higher income settings and 
have recently been validated in LMIC settings.(36-38) 
 
In a recent prospective study from Lesotho, Labhardt et al found that 94% of patients 
with a confirmed VL >80 copies/ml but <1000 copies/ml had resistance mutations on 
genotype, suggesting that local definitions of virological failure are not sensitive 
enough.(38) Similarly, in a large observational cohort from South Africa, Hermans et al 
found that low level viraemia (defined as at least one episode of VL 51 – 999 copies/ml) 
was a strong predictor of subsequent virological failure and change to an alternative 
regimen.(37) While a virological “blip”, or transient episode of low level viraemia has long 
been thought not to have clinical significance, this study found that even a single 
detectable VL >50 copies/ml was associated with poorer treatment outcomes.(10, 37)  
 
It is important to note that virological “blips” may be subject to the performance of the 
particular quantification assay used. As Taiwo et al point out, not all VL assays are equal. 
Although there is generally good correlation at higher VL levels, “inter- and intra-assay 
variability may be significant around the lower quantification limits”.(39) Whether or not 
a “blip” is recorded thus depends not only on the level of detection of the assay, but also 
on the type of assay used.(39)  
 
Several large studies have shown the importance of undetectable VL in reducing HIV 
transmission. Undetectable VL therefore provides not only therapeutic benefit, but is also 
a strategy to reduce new HIV infections.(12, 13) 
 
2.6 Virological resistance 
 
Virological resistance has been described in African adolescents, with prevalence as high 
as 67% described in Zimbabwean patients with virological failure on non-nucleoside 
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reverse transcriptase inhibitors (NNRTIs).(40) In a cohort of children and adolescents in 
the Central African Republic, more than half of subjects with virological failure had 
resistance to first-generation NNRTIs and 24% had a major drug resistance mutation to a 
protease inhibitor (PI).(41) These findings were in settings without routine VL monitoring, 
where clinicians were guided only by clinical and immunological factors to diagnose 
treatment failure, potentially allowing resistant mutations to accumulate. In a Tanzanian 
cohort of children and adolescents, 90% of subjects with virological failure had at least 
one major drug resistant mutation, and NNRTI resistance was found in 81%. No PI 
mutations were found, despite 15% of the cohort being on a boosted PI. Routine VL 
monitoring was also not performed in this setting.(42)  
 
In the South African context, where routine VL monitoring is available, a public health 
approach has been taken to virological resistance. As the drug resistance mutations that 
develop after failure of an NNRTI-based regimen are predictable, a standardised PI-based 
regimen has been chosen to achieve virological suppression in this case. National 
guidelines dictate a swift change to a PI-containing regimen for patients with two 
consecutive VL >1000 copies/ml on an NNRTI-based regimen. Within the public sector, 
HIV genotypes are performed only on patients with virological failure on a PI-containing 
regimen.(34) No studies describing prevalence of PI resistance in South African 
adolescents could be identified. A study of South African adults with virological failure on 
a PI-regimen found that 16.4% had at least one major PI mutation. The authors 
concluded that poor adherence is the leading cause of virological failure on PI-based 
ART.(43) 
 




In order to achieve virological suppression, adherence to ART needs to be at least 95%.(9)  
World-wide evidence suggests that adolescents struggle to achieve these stringent 
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adherence requirements, and have poorer virological outcomes than other age 
groups.(31) In a 2014 systematic review of cross-sectional studies in which adherence 
was defined as undetectable viral load or self-report of at least 85% of medication taken, 
Kim et al found that overall adolescent adherence was 62%, with much regional 
variation.(15) In North America, adherence was only 53%, while in Africa and Asia it was 
84%, suggesting that high income countries do not necessarily have better adolescent 
adherence.(15) Similarly, in a French perinatally-infected cohort, Dollfus et al describe 
undetectable viral load in only 54,5% of adolescents on ART, compared to 45,9% in a 
similar American cohort reported by Kahana et al.(44, 45)  
 
Ferrand et al performed a systematic review on the prevalence of virological suppression 
in adolescents after one year on ART. Results were extremely variable, and ranged from 
27 – 89%. When the time constraint was removed and adolescents at any time since start 
of ART were included, similar results of 28 – 87% were found. However, the authors 
concluded that the main finding of the study was the “paucity of data on virological 
outcomes among adolescents with HIV”.(16) 
 
In 2009, Nachega et al analysed data from a private sector HIV-management programme 
in southern Africa and found that adolescents were less adherent than adults as well as 
having lower rates of virological suppression (at a level of detection of <400 copies/ml).  
In this cohort, 58% of adolescents had ever suppressed compared to 72% of adults. In 
addition, adolescents had lower rates of viral suppression at all time points after the start 
of ART, with a marked decline after the first VL at month 6. At month 6, virological 
suppression stood at 63% in adolescents compared to 69% in adults. At month 12, this 
had dropped to 46% compared to 62% in adults. By month 24 there was further decline 
to 44% in adolescents, while adults remained stable.(8) 
 
A similar pattern of decreasing rates of virological suppression (<400 copies/ml) at 
increasing time on ART was found in a prospective cohort at a community clinic in Cape 
Town, South Africa. While ART-naïve adolescents had high rates of virological suppression 
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at week 16 on treatment (97.3%), this fell rapidly by week 32, declining to 27.3% by week 
48 compared to 63% in young adults.(14)  
 
In the Central African Republic, Mossoro-Kpinde et al performed a cross-sectional 
analysis on a mixed group of children and adolescents (median age of 12 years) receiving 
ART. At a level of detection of 20 copies/ml, only 40% of children had undetectable VL. Of 
the remaining children with detectable VL, 97% had VL >1000 copies/ml. (41) A similar 
high prevalence of non-suppression was found in children and adolescents in Togo, 
where 36% of subjects had  VL <40 copies/ml, and 51.6% had VL >1000 copies/ml.(46) 
 
More encouragingly, Collins et al examined prospective data from the United Kingdom 
and Ireland to determine clinical status at the last paediatric visit before transition to 
adult services. In a largely vertically-infected cohort with a median age of 17.4 years, 74% 
of subjects on ART had VL <400 copies/ml, while 60% had VL <50 copies/ml. These results 
did not include the 13% of the cohort which was not on ART due to treatment 
interruption at the time of transfer.(4) 
 
A high prevalence of virological suppression was found in a recent cross-sectional study 
from Cape Town, in which 76% of vertically-infected adolescent subjects had HIV VL <50 
copies/ml. However, it is worth noting that these were all younger adolescents, with a 
median age of 12 years.(30) The association between age in adolescence and VL will be 
discussed later in this chapter. 
 
In summary, the prevalence of detectable VL in adolescence varied widely by context and 
study. This variation could be due in part to differing thresholds of detection, but even 
those studies reporting at higher thresholds tended to find sub-optimal suppression. 
With a few notable exceptions, many studies reported undetectable VL in adolescents at 
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less than 50%. The consensus is that adolescents have a higher prevalence of viraemia 
than adults. 
 
2.7.2 Retention in care 
 
Retention in care varies across contexts but in general has been found to be worse 
among adolescents and youth than among older adults.(31, 47-50) This has clear 
implications for treatment outcomes, as adherence to treatment and ultimate virological 
suppression are only possible if there is retention in care.(48) A systematic review of 
youth (age 15 – 24 years) in South Africa found that overall retention in care was 
83%.(49) Individual studies from elsewhere have found varying results. In a retrospective 
study from Uganda, adolescent retention in care was only 65%, which was similar to adult 
figures for the same district.(51) Much better retention was found in a study from 
Thailand, where Sudjaritruk et al describe loss to follow up (LTFU) in a cohort of vertically-
infected adolescents as only 1,2%, or 0.3 events per 100 PY. However, as the endpoint of 
this study was virological rebound post-suppression, a substantial proportion of screened 
subjects (39%) were excluded as they did not have a sustained period of virological 
suppression. This may have introduced a bias towards more stable patients.(52) In a 
prospective South African adolescent cohort described by Nglazi et al, LTFU was 7.2 per 
100 PY overall, although this was only 3.9 per 100 PY when restricted to vertically-




The incidence of detectable VL in adolescence is not well understood due to a lack of 
longitudinal data. An adult study from Kwazulu Natal, South Africa, described incidence of 
“virological failure” (defined as a single VL >1000 copies/ml at least 6 months after 




In a South African study where “virological failure” was defined as two VL >1000 
copies/ml after at least one VL <400 copies/ml, the findings were that adolescents 
experienced virological failure at a rate of 8.2 per 100 PY. This is significantly higher than 
the 5 per 100 PY experienced by young adults.(14) 
 
Finally, in a vertically-infected Thai cohort, Sudjaritruk et al described the incidence of 
single VL >1000 copies/ml following sustained suppression, as 3.4 per 100 PY.(52) 
 
Due to differing definitions, it is hard to compare incidence across studies. In the only 
study comparing adolescent to adult outcomes, the incidence of viraemia was higher in 
the adolescent group.(14) 
 
2.7.4 Duration of detectable VL 
 
There is paucity of data on duration of detectable VL over a specified time period. In the 
only identified study explicitly describing duration of detectable VL, person-time spent 
with VL >400 was described in a large cohort of vertically-infected subjects in the United 
States aged 7 to 30 years. Total follow-up time spent with VL >400 was 34% for the whole 
cohort but only 30% of the study time contributed by those aged 13 – 17 years old.(54)  
 
2.7.5 Viral rebound and re-suppression 
 
Collier et al performed one of the few studies to examine both re-suppression and 
duration of detectable VL. In this adult cohort from Kwazulu-Natal, South Africa, 57% of 
subjects with a single VL >1000 copies/ml on PI-containing ART re-suppressed, after a 
median of 8 months.(53) 
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A 2015 study by Childs et al examined outcomes after viral rebound (defined as a 
confirmed VL >400 copies/ml after suppression on first line ART) in a cohort of children 
and adolescents in the United Kingdom and Ireland. While half of the cohort was swiftly 
switched to an alternative regimen, a third re-suppressed on the same regimen. In the 
group that switched, 85% were suppressed at 12 months, and 73% at 24 months. In the 
group that re-suppressed without switching, 39% remained suppressed at the most 
recent follow-up (median 28 months), while 61% had a further VL >400 copies/ml.(55)  
 
Conversely, Sudjaritruk et al studied outcomes after sustained virological suppression in a 
vertically-infected Thai cohort. A single raised VL >1000 copies/ml was experienced by 
13% of the cohort.(52) Nachega et al found that in the early days of ART in southern 
Africa (between 1999 and 2006), adolescents who suppressed initially were at higher risk 
for viral rebound at all time points after commencing ART.(8) 
 
The differing definitions and methodology make it difficult to compare studies, though all 
point to the notion that virological status is not static. Patients who are suppressed at 
one time point may rebound. Those with detectable VL may suppress at a later time 
point, even without a regimen change. Despite the potential for re-suppression displayed 
in the study by Childs et al, adolescents in Nachega et al’s study were found to be at 
higher risk of virological rebound than adults.(8, 55) 
 
2.8 Factors associated with detectable VL 
 
In chronic illnesses as diverse as congenital cardiac disease, diabetes and HIV, it is well 
documented that medication adherence decreases during adolescence, while morbidity 
and mortality increase inversely.(9) Normal developmental characteristics such as the 
desire to be the same as one’s peers, poor planning for the future and rebellion against 
parental figures can hinder adolescent adherence to medication in many chronic 
illnesses.(56) In the context of HIV, stigma and the effects of familial HIV on the 
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household pose additional adherence challenges.(48) Stigmatising medication side-
effects such as lipoatrophy may also impact on medication adherence. In times of 
particularly high pill burden (such as during treatment for multidrug-resistant 
tuberculosis), polypharmacy may contribute to poor adherence.(9) 
 
Multiple factors have been associated with poor adherence to ART and detectable HIV VL 




In the adolescent population, increasing age has been associated with worsening 
outcomes across multiple studies. Both anti-retroviral (ARV) non-adherence, and its 
outcome of HIV viraemia, have been found to increase as adolescence progresses. A 
Tanzanian study found increased odds of poor adherence and virological failure on 
transition to adolescence, which only became more marked as adolescence 
advanced.(57) In a Thai study, Suaysod et al found that children older than 13 years were 
at higher risk of treatment failure (58), while Adejumo et al noted that older adolescents 
were at risk of poorer adherence compared to children younger than 15 years.(19) In a 
US study each year of age carried a 10% increase in odds of non-adherence measured by 
self-report.(56) More recently, a South African study found that compared to adolescents 
younger than 12 years, adolescents aged 12 – 14 years carried a 2.4 times higher risk of 
having a VL >50, and a 2.98 times higher risk of having a VL >1000.(30) Older adolescents 
have also been found to be at higher risk of attrition from care.(51) 
 
A large US study found that adolescents aged 13 – 17 years as well as youth aged 18 – 30 
years spent more time with a VL >400 copies/ml compared to a younger age-group of 7 – 
12 years (30% and 44% compared to 22% of person-time respectively).(54) 
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A one year cohort analysing routine programme data from Uganda found that both 
children and adolescents experienced more virological non-suppression (defined as VL 
>1000 copies/ml for plasma or VL >5000 copies/ ml for dry blood spots) than adults. 
Children under 5 years had the highest prevalence (29%), followed by adolescents 15 – 19 
years (27%). This was somewhat lower in children aged 5 – 9 and 10 – 14 years, at 23% 
for both. After adolescence, prevalence of non-suppression dropped steadily across five 
year age-bands until it reached 7% in those 35 years and older.(59)  
 
Makadzange et al performed a similar analysis of children and adolescents in Zimbabwe, 
and found a 28% prevalence of a single VL >1000 copies/ ml in children aged 0 – 15 years. 
This was higher in older adolescents aged 15 – 19 years, at a prevalence of 37%. Within 
this study, the role of increasing age was complicated by whether ART was started in 
childhood or adolescence. In those who initiated ART in adolescence, each additional 
year of age at the time of evaluation was associated with a 2.4 times increased risk of VL 
>1000 copies/ml.(40) 
 
In summary, the evidence from multiple contexts suggests that older adolescents are at 




Worldwide, there are more adolescent girls than boys living with HIV, with 65% of new 
infections occurring in girls.(7) The gender ratio tends to be equal among vertically-
infected youth. (9) There have been conflicting findings on gender and adherence in 
adolescents, with some studies reporting better adherence associated with female 
gender, and others reporting the opposite.(9)  
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In a South African vertically-infected cohort, Brittain et al found that male gender was 
associated with a 2.2 times increased odds of having a VL >50 copies/ml.(30) In contrast, 
Muri et al found that female gender was associated with a 2.57 times increased risk of VL 
>1000 copies/ml in a cross-sectional study of children and adolescents in Tanzania.(42) In 
contrast Kahana et al described no association between gender and virological 
suppression in a large American study of over 2000 youths living with HIV, in both 
vertically and horizontally-infected cohorts.(44) Similarly, in a vertically-infected Thai 
cohort studied by Sudjaritruk et al, gender was not associated with virological rebound 
post suppression.(52) 
 
2.8.3 Time on ART 
 
Several studies of ART-naïve adolescents have found an increased rate of unsuppressed 
VL with increasing time since start of treatment. As mentioned previously, both Nglazi 
and Nachega noted that adolescent suppression tended to drop off steeply after the first 
VL measurement (at either 16 weeks or 6 months).(8, 14) However, it is less clear 
whether time on ART affects viral suppression in adolescents who initiated ART as 
children. 
 
Pill-fatigue is a common complaint of vertically-infected youth (who have often been on 
treatment since early childhood), and has been associated with poor adherence.(60, 61) 
However, Xu et al found that number of years on ART was not associated with VL >1000 
copies/ml among Thai vertically-infected adolescents.(62) Similarly, Kahana et al found 
that number of years since HIV diagnosis was not associated with viral suppression 
among a mixed group of vertically and horizontally-infected American adolescents. (44)  
 
In a Zimbabwean adolescent cohort, Makadzange et al found that time on ART was 
associated with having a VL >1000 copies/ml. This however depended on whether the 
subject had started ART before or after age 10 years. In adolescents who initiated 
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treatment as children, time on treatment of 4 or more years was associated with an 
increased risk of raised VL. However, in those who initiated treatment as adolescents, 
increasing time on ART was associated with decreased risk of raised VL.(40) This stands in 
contrast to the findings of Nglazi et al and Nachega et al, who both found that 
adolescents initiating ART had reasonable virological suppression in the short term, but 
this was not sustained past the first test of VL.(8, 14) 
 
2.8.4 Age at ART initiation 
 
Conflicting evidence exists as to whether the age of ART initiation is associated with VL 
outcomes. Makadzange et al found that older age of starting ART was associated with 
raised VL. In this study, 39% of those who started ART between 10 and 19 years of age 
had a current VL >1000 copies/ml, compared to 26% in those who started below 10 
years.(40) However, the opposite finding was reported by Muri et al, in a mixed cohort of 
children and adolescents (median age of 11 years) in rural Tanzania. In this cohort, older 
age at ART initiation decreased the odds of having VL >1000 copies/ml at cross-sectional 




In summary, accounting for poor adolescent outcomes on ART is difficult due to the lack 
of data – and particularly disaggregated data - in the field. This is further confounded by 
the absence of a gold standard for measuring adherence, which contributes to the 
conflicting results found in different studies. 
 
The HIV VL has been found to be the most sensitive measure of adherence to ART, as well 
as a proxy for disease progression and risk of onward transmission. However, there is a 
lack of standardisation across studies, and different VL thresholds have been used at 
different times and in different contexts. Moreover, depending on study design and local 
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definitions, outcomes such as virological failure may depend on single or multiple 
measurements. This variability makes it difficult to compare studies. 
 
Worldwide, adolescents have been found to have poorer adherence and correspondingly 
worse VL outcomes than other age groups. As most studies are cross-sectional, 
prevalence is the most common outcome measured. This varies widely according to study 
design and context. However, all comparative studies reviewed found that the 
prevalence of virological non-suppression was higher in adolescents than in adults. 
 
Incidence of detectable VL or virological failure is a less studied outcome, but what data 
exist show similarly worse outcomes for adolescents than adults. Virological rebound and 
subsequent re-suppression are common in adolescents and adults, although adolescents 
are at higher risk of rebound. There is very little data available concerning the duration of 
detectable viraemia.  
 
Conflicting data exist around most factors associated with unsuppressed VL. The 
literature finds for and against age of ART initiation, time on treatment and gender as 
predictors of poor adherence or detectable VL. However, older age in adolescence has 
been strongly associated with poorer adherence and greater likelihood of non-
suppression. This is in keeping with the evidence of high mortality in older adolescents. 
 
A limitation of much of the literature is the high proportion of cross-sectional studies, 
which are not able to map dynamic processes of adherence and virological response. In 
light of this, multiple authors have called for additional longitudinal studies of ARV 







This study investigates the patterns of detectable viral load (VL) in a cohort of HIV 
positive adolescents on ART. Quantitative research methodology was used, in the form of 





The study aimed to describe the burden of persistent measurable viral load in a cohort of 




The main objectives of the study were as follow:  
1. To describe the prevalence of VL above 100 copies/ml (at two testing time points 
at least two months apart) in HIV positive adolescents on ART. 
2. To describe the incidence of VL above 100 copies/ml in a cohort of HIV positive 
adolescents on ART. 
3. To describe the duration of time spent with elevated viral load in the same 
population. 





3.4 Study Design 
 
 
A retrospective cohort study using medical records was performed. The period under 
review was from 1 January 2002 until 31 December 2016. 
 
3.4.1 Study Population 
 
The study population comprised all patients age 10 – 19 years who attended Groote 
Schuur Hospital’s Adolescent HIV Clinic from 2002 (when the clinic began) to the end of 
2016. The age-limits of this study were chosen to reflect the WHO definition of 
adolescence, i.e. 10 – 19 years. Qualifying study subjects were required to have spent at 
least 24 months on ART after turning 10 in order for a trend within adolescence to be 
established. Data from patients who were subsequently transferred out of the service or 
who were older than 19 years at the time of review were included for that period of time 
that the subject met inclusion criteria. 
 
Inclusion criteria 
1. HIV-positive, on ART >24 months. 
2. At least 10 years and no older than 17 years at study entry 
3. Followed up for at least 24 months at Groote Schuur Hospital. 
 
Exclusion criteria 
1. Pre-ART, or on ART <24 months. 
2. Not in the age range 10-19 years over the study period 




3.4.2 Outcomes of Interest 
 
The primary outcome was two consecutive detectable viral loads (viral load of at least 
100 copies per millilitre), at least two months apart. 
 
Over the period under review, the limit of virological detection varied between 20 and 
100 copies per millilitre depending on the assay used. In order to standardise 
interpretation, detectable viral load was defined as greater than or equal to 100 copies 
per millilitre.  
 
Regular viral load monitoring was always available in the clinic over the study period. 
Clinic protocols dictated that viral load was monitored annually in stable patients, while 
an unsuppressed viral load was repeated approximately two months after an adherence 
intervention. This protocol remained unchanged over the years under study. However, 
clinician discretion and variable patient attendance meant there was variation in the 
frequency of patient monitoring.  
Where available, data on resistance genotyping were collated. 
Time lost to follow-up was captured separately, and contributed to the duration of time 
spent with a high viral load. It was not, however, regarded as a new high VL event in a 
patient who was previously virologically suppressed. Loss to follow-up was defined as not 
returning to care for at least 12 weeks after the appointment date. 
All deaths that occurred during the study follow-up period were recorded. 
 
3.5 Study procedure 
 
A search was performed using Groote Schuur Hospital’s Information Systems as well as 
separately captured records from the clinic itself. All folders of patients who attended the 
clinic for any time during adolescence were pulled and reviewed against inclusion criteria.  
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Once eligible subjects were identified, relevant information was extracted from their 
medical records. 
 
The data extracted included demographic data, mode of HIV acquisition, date of 
diagnosis, date of first ART, ART regimens, VL measurements, time lost to follow up and 
mortality. Other additional data that were collected but are beyond the scope of this 
project are shown in Annexure 2. 
 
3.6 Patient safety and confidentiality 
 
This was a non-interventional study with no direct patient contact using retrospective 
data. Strict confidentiality was maintained from the point of subject identification. Only 
the investigators were involved with data-capturing, and only they had access to the 
database throughout the study period. The database is stored in an access-controlled 
computer in a locked room. 
 
3.7 Data management and statistical analysis 
 
Data were directly entered electronically into a password protected database using 
KoBoToolbox, after which it was exported to STATA Version 14 (Stata Corporation, 
College Station, Texas, USA) to be checked and verified before analysis. Data were 
cleaned and queries addressed using standardised approaches.  
 
Demographic characteristics and clinical findings were tabulated to provide baseline 
descriptions of the study population. After continuous variables were assessed for 
normality they were all summarised using medians with interquartile ranges as they 
showed significant skewness. Categorical variables were depicted as percentages and 
where necessary are shown together with their 95% confidence intervals.  
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The χ2 test or Fisher’s exact tests were used to assess the strength of association 
between two categorical variables as appropriate while association between two 
continuous variables was tested with the Mann-Whitney test.  
 
For estimation of incidence, time at risk was defined as total follow-up time. This was 
further stratified by gender, age at outcome, age at ART initiation, time on ART and 
calendar year.  
 
The incidence of detectable viral load was estimated by calculating the rate of primary 
outcome events over the time period the subjects were in the study. All rates were 
calculated per 100 person years (PY) and included 95% confidence interval estimates. 
Relative risk ratios and their 95% confidence intervals were estimated using the Mantel–
Haenszel method with and without adjustment for potential confounders.  
 
Subjects who entered the study with detectable VL were categorised as having met the 
outcome at second consecutive detectable VL. 
A significance level was set at a two-tailed P<0.05 for all analysis.  
 
3.8 Ethical considerations 
 
The protocol was approved by the Human Research Ethics Committee of the University of 
Cape Town (HREC REF: 899/2016), and a waiver of consent was granted. Institutional 








Of the 482 patients who attended clinic during adolescence, seven were not on 
antiretroviral therapy (ART) for at least 24 months, while 148 did not attend clinic for at 
least 24 months as adolescents (this includes patients who transferred out or were lost to 
follow up in the first two years in care [n=91], as well as children who had not yet been 
adolescents for at least 24 months [n=57]). Therefore 327 patients met the entry criteria. 
 
4.2 Baseline characteristic of study population 
 
A total of 327 subjects were included for analysis of which 170 (52%) were male. The 
median age of study entry was 10.6 years (IQR 10 - 12.8), and exit was at 16.9 years (IQR 
14.9 - 19.1). Median time spent in the study was 4.9 years (IQR 3.6 - 6.6). The number of 
patients followed up per calendar year increased over the follow-up period, peaking in 
2014 at 296 subjects (Figure 4.1). 
 
 
Figure 4.1 Number of adolescents seen per calendar year. 
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The majority of the cohort acquired HIV infection vertically (n=314; 96%), with small 
proportions of horizontal infections or unknown mode of infection. 
 
Median age of diagnosis was 5.2 (IQR 1.3 - 9.1) years and of starting ART was 7.2 (IQR 3.2 
- 9.9) years. The median time spent on ART was (IQR 1.8 - 7.6) 4.4 years at study entry, 
and 10.2 (IQR 7.5 - 12.5) years at study exit. 
 
Over the duration of follow-up, there were 783 drug changes. Of all regimens used, 49% 
contained non-nucleoside reverse-transcriptase inhibitors (NNRTIs), and 47% contained 
protease inhibitors (PIs). In addition, 3% of all regimens were non-suppressive “holding” 
regimens, and 0.5% were Darunavir/ Ritonavir – containing “third line” regimens, 
exclusively used in subjects with confirmed PI resistance on genotype. 
 
 
Table 4.1 Baseline characteristics of HIV infected adolescents (N=327) 
Variable 
 















Age (years)   
 Study entry   10.6 (10 - 12.8) 
Study exit  16.9 (14.9 – 19.1) 
Diagnosis  5.2 (1.3 – 9.1) 
ART initiation  7.2 (3.2 – 9.9) 
Follow-up time   4.9 (3.6 – 6.6) 
Duration of ART (years) 
At study entry 
At study exit 
  
4.4 (1.8 – 7.6) 
10.2 (7.5 – 12.5) 








NNRTI = Non-nucleoside Reverse Transcriptase Inhibitor 





4.3 Prevalence of detectable viral load (VL) 
 
A total of 2468 viral loads were performed during the follow-up period of which 885 
(36%) were detectable at a threshold of >100 copies/ml. Ninety-five subjects (29%) had 
detectable VL on entry, while 98 (30%) had detectable VL at exit. There was a median of 9 
VL performed per subject (IQR 6 - 9), with a range from 2 to 21. 
 
In total, 111 (33.9%) of patients had undetectable VL for the duration of the follow-up 
period, while 16 subjects (4.9%) never suppressed. A further 57 (17.4%) subjects had a 
single detectable VL followed by virological suppression at next bloods: they therefore 
did not achieve the primary outcome.  
 
Over the follow-up period, 159 (49% [95% CI 43% – 54%]) subjects experienced 
confirmed detectable VL. A total of 86 (51%) out of 170 boys experienced detectable viral 
load compared to 73 (47%) out of the 157 girls; p=0.46.  
 
At first detectable VL, median age was 13.8 (IQR 11.2 – 15.5) years, and median time on 
ART was 6.3 (IQR 3.4 - 9.0) years. Subjects who experienced detectable VL had a median 
age of starting ART of 7.8 (IQR 3.2 – 9.9) years, compared to 6.1 (IQR 2.6 – 9.6) years in 
those who did not (p=0.026). When age of starting ART was analysed as those <10 years 
compared to those 10 years or older, 47% of subjects younger than 10 years vs 53% of 















4.4 Re-suppression and viral rebound 
 
Of the 159 subjects who experienced detectable VL, 102 (64%) re-suppressed, of which 
38 (37%) had a subsequent detectable VL. Of these, 22 (58%) re-suppressed, although 6 
(27%) of these had a further detectable VL.  
 
Table 4.2 Prevalence of detectable viral load (N=327) 
Variable  n (%)/ median (IQR) 
Number of VL performed per subject 9 (6 – 9) 
Number of subjects with:  
Any two consecutive VL > 100 copies/ml 159 (48.6) 
Single VL > 100 copies/ml 57 (17.4) 
No VL < 100 copies/ml 16 (4.9) 
No VL > 100 copies/ml 111 (34) 
Confirmed detectable VL outcome#  159 (100) 
Male 86 (54) 
Female 73 (46) 
Episodes of study outcome# by subject  
0 168 (51.3) 
1 121 (37) 
2 32 (9.8) 
3 6 (1.8) 
Age of first study outcome# VL (years)  13.8 (11.2 – 15.5) 
Years on treatment at first outcome VL   6.3 (3.4 – 9) 
VL >100 copies/ml at study entry  95 (29) 
VL >100 copies/ml at study exit  98 (30) 
Confirmed detectable VL at exit  79 (24) 
Genotyped PI Resistance  6 (1.8%) 




















Figure 4.2 Re-suppression and viral rebound 
 
 
Distinct episodes of detectable VL separated by at least one VL <100 copies/ml can be 
described. Of the 159 subjects who experienced detectable VL, 121 (76%) had a single 
episode, 32 (20%) had two episodes, and 6 (4%) had three episodes.  
 
Six of the 159 (4%) subjects had genotyped resistance to protease inhibitors. Four of 
these never suppressed, while two entered the study with detectable VL, but later 
suppressed on Darunavir/ Ritonavir – containing “third-line” regimens. 
 
The 16 subjects who never suppressed were comprised of nine females and seven males. 
Fifteen (94%) were infected vertically. For the 16 subjects who never suppressed, the 
median time on treatment before study entry was 4.2 (IQR 1.2 - 8.3) years. The median 
age at start of ART was 7.9 (IQR 3.5 - 12.2) years, and median age of study entry was 13.2 
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The 111 individuals who never had detectable VL were comprised of 55 (49.6%) females 
and 56 (50.5%) males. Five (4.5%) subjects were horizontally-infected, one (0.9%) had an 
unknown mode of transmission and 105 (95%) were vertically-infected. The median age 
of study entry for this group was 10.0 (IQR 10.0 – 12.6) years and age of starting ART was 
5.2 (IQR 2.8 - 9.4) years. The median time on ART before study entry was 5.4 (IQR 2.6 - 
7.8) years.  
 
Table 4.3 Comparison by detectable viral load categories 
A.  Study outcome detectable VL (two consecutive VL > 100 copies/ml) versus no study outcome 
Variable 
Confirmed outcome VL# 
(n [%]/median [IQR]) n=159 
 No study outcome 
(n [%]/median [IQR]) n=168 
P 
Male sex 86 (54)  84 (50) 0.460 
Horizontally acquired HIV 4 (3)  5 (3) 0.799 
Age at ART initiation (years) 7.8 (4.3 – 10.2)  6.1 (2.6 – 9.6) 0.026 
Age at study entry (years) 10.9 (10.0 – 13.6)  10.0 (10.0 – 12.5) 0.024 
Follow-up time in study (years) 5.1 (3.8 – 7.1)  4.7 (3.4 – 6.2) 0.021 
     
B.  No single detectable VL versus at least one detectable VL (any VL > 100 copies/ml) 
Variable 
No single detectable VL 
(n [%]/median [IQR]) n=111 
 At least one detectable VL 
(n [%]/median [IQR]) n=216 
P 
Male sex 56 (50)  114 (53) 0.690 
Horizontally acquired HIV 5 (5)  4 (2) 0.165 
Age at ART initiation (years) 5.2 (2.8 – 9.4)  7.6 (3.4 – 10.1) 0.048 
Age at study entry (years) 10.0 (10.0 – 12.6)  10.7 (10.0 – 13.0) 0.266 
Follow-up time in study (years) 4.7 (3.5 – 6.1)  5.1 (3.7 – 7.0) 0.063 
     
C.  Always detectable VL (> 100 copies/ml) versus at least one undetectable VL 
Variable 
No undetectable VL 
(n [%]/median [IQR]) n=16 
 One or more undetectable VL 
(n [%]/median [IQR]) n=311 
P 
Male sex 7 (44)  163 (52) 0.499 
Horizontally acquired HIV 1 (6)  8 (3) 0.381 
Age at ART initiation (years) 7.9 (3.5 – 12.2)  7.1 (3.2 – 9.9) 0.395 
Age at study entry (years) 13.2 (11.1 – 13.6)  10.3 (10.0 – 12.8) 0.007 
Follow-up time in study (years) 4.0 (3.6 – 5.5)  5.0 (3.6 – 6.7) 0.159 














4.5 Incidence of detectable viral load 
 
A total of 327 adolescents were followed up for a median of 4.9 (IQR 3.6 – 6.6) years. The 
total follow-up time was 1723 PY of which 885 (51%) were contributed by males. The 159 
subjects who experienced detectable VL contributed 880 (51%) PY of the follow-up time.  
 
In total 203 distinct episodes meeting the study outcome of two consecutive VL > 100 
copies/ml) occurred over the follow up period with an overall rate of 11.8 (95% CI 10.2 – 
13.5) per 100 PY over the follow-up period.  
 
The rate of detectable VL increased with increasing age (Table 4.4) with an overall 
relative risk of 1.24 (95% CI 1.17 – 1.31) for every increasing year of adolescence 
(p<0.0001). See Figure 4.3. 
 
Table 4.4 Rate of detectable viral load by age 
Age (years)  
Rate per 100 PY 
(95% Confidence Interval) 
10  1.8 (0.6-5.7) 
11  5.7(3.2-10.3) 
12  8.3(5.2-13.1) 
13  12.4 (8.5-17.9) 
14  8.3 (5.3-13.1) 
15  12.7 (8.7-18.7) 
16  15.4 (10.6-22.5) 
17  17.3(11.7-25.6) 
18  18.4 (11.7-28.8) 
19  39.5(27.1-57.6) 
PY = Person Year; VL = HIV Viral Load 
 
 
The age of adolescents was categorised into age-bands to fit with early, middle and late 
adolescence. In this analysis, subjects aged 10 – 12 years had a rate of detectable VL of 
5.6 (95% CI 3.9-7.9) per 100 PY. Those aged 13 – 15 had a rate of 11.1 (95% CI 8.8-14) per 
100 PY and those aged 16 – 19 had a rate of 19.9 (95% CI 16.4-24.3) per 100 PY.  
 
The rate of detectable VL was 12.1 (95% CI 10.0 – 14.6) per 100 PY in males and 11.5 
(95% CI 9.4 – 14.0) per 100 PY in females. The trend in the age rate was similar in males 




Figure 4.3 Rate of detectable VL by age and sex 
 
 
The rate of detectable VL decreased with increasing time on ART. For subjects who had 
been on ART for less than 5 years, the rate was 23.7 (95% CI 17 – 33) per 100 PY, while for 
those who had been on ART between 5 and 10 years, the rate was 12.9 (95% CI 10.5 – 
15.8) per 100 PY. The rate of detectable VL was lowest in subjects who had been on ART 
for greater than 10 years, at 8.9 (95% CI 7.1 – 11.1) per 100 PY. 
 The risk of detectable VL decreased by 13% per each additional year on ART [unadjusted 
RR 0.87 (95% CI 0.83 – 0.91)]. 
 
The rate of detectable VL increased by calendar year during the study period. Unadjusted 
risk ratio was 1.19 (95% CI 1.13 – 1.26). When adjusted for age, the risk ratio was 1.15 




Figure 4.4 Rate of detectable VL by calendar year 
 
4.6 Time spent with detectable VL 
 
Of the total follow-up time of 1723 PY, the 159 subjects who experienced detectable VL 
contributed 880 (51%) PY. Of these, 370 years were actually spent with detectable VL: 
this comprised 22% of the total follow-up time, but 42% of the time contributed by those 
subjects who experienced detectable VL. Females contributed 173 (47%) of the 370 PY 
spent with detectable VL, while males contributed the remaining 197 (53%) years. Time 
with detectable VL comprised 21% of the total follow-up time contributed by females, 
and 22% of that contributed by males, (p=0.4).  
 
Participants experienced up to three separate episodes of detectable VL during the 
follow-up period. The median duration of the first episode was 1.5 (IQR 0.8 - 2.5) years, 
for the second was 1.3 (IQR 0.8 - 2.5) years and for the third was 1.1 (IQR 1.1 - 1.2). In all 
cases, the third episode was ended by study exit. The overall duration of time spent with 
detectable VL increased with increasing numbers of episodes, as can be seen in table 4.5.  
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The median duration of suppression after first detectable VL was 1.3 (IQR 0.7 - 2.8) years, 
while that of suppression following a second episode of detectable VL was 0.9 (IQR 0.4 - 







4.7 Loss to Follow-up 
 
Overall, there were 101 episodes of loss to follow up, involving 69 individuals (21.1% 
prevalence). Ultimately, 15 did not return to care within the study period (4.6%). The rate 





There were 4 deaths during the study period: one traumatic, and three HIV related for a 
mortality rate of 0.2 per 100 PY (0.08 – 0.6). All deaths occurred among vertically-infected 
subjects. All three HIV related deaths occurred in males. One death occurred at the age of 
14 years and two at the age of 18 years. The youngest death occurred in a subject who 













n (%)/ median (IQR) 
Total follow-up time (Person Years) 1723 (100) 
Males 885 (51) 
Females 838 (49) 
Follow-up time contributed by subjects with:  
No detectable VL 843 (49) 
Confirmed detectable VL 880 (51) 
Time spent with detectable VL 370 (100) 
Males 197 (53) 
Females 173 (47) 
Total time with detectable VL, by number of episodes   
1 episode (n=121) 1.5 (0.8 – 2.6) 
2 episodes (n=32) 2.8 (2.1 – 4.4) 
3 episodes (n=6) 3.5 (2.8 – 3.7) 
Duration of suppression post detectable VL   
1st suppression (n=102) 1.3 (0.7 – 2.8) 
2nd suppression (n=22) 0.9 (0.4 – 1.8) 
VL = HIV Viral Load, NB. Detectable viral load=two consecutive VL> 100 copies/ml 
 36 
did not meet criteria for confirmed detectable VL, as he had been virologically suppressed 
prior to a 19-month period of loss to follow-up shortly before his death. One of the 
subjects who died at 18 years had detectable VL for the full 4.7 years of follow-up. The 









Our study shows that detectable viral load (VL) is common in a cohort of adolescents on 
ART being followed up at a specialised adolescent HIV clinic. Those who experienced 
detectable VL spent a significant proportion of their follow-up time in this state although 
the period was interrupted by periods of viral suppression. While there was no 
association with gender, there was a strong association with age, with older adolescents 




Our data show that almost half of adolescents experience detectable VL, although most 
also experience periods of virological suppression. In one published systematic review, 
Ferrand et al found adolescent virological suppression to range from 27 – 87% at any 
time since start of ART.(16) In a large meta-analysis, Kim et al estimated that world-wide 
adolescent adherence (based largely on VL, but also on self-report) was 62%.(15) . It is 
difficult to compare our own findings with published literature, as almost all identified 
studies are cross-sectional, with widely varying results. A further challenge arises from 
differing definitions of detectable VL depending on the limits of the assay or the study-
specific definitions in use. 
 
5.2.1 Subjects with no detectable VL 
 
One third of the subjects in our study never experienced any detectable VL over the 
follow-up period. The only identified longitudinal study reporting similar findings 
reported that 29% of the cohort experienced no detectable VL during follow-up in a 
vertically-infected American cohort with a mean follow-up time of 4.6 years.(64) Similar 
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proportions of virological suppression were reported by several cross-sectional 
studies.(41, 44, 46) Our study was able to demonstrate that 34% of adolescents showed 
no rebound detectable VL over a sustained length of time. This group was similar to the 
rest of the cohort in its gender and age of study entry profile, but had a younger age of 
ART initiation and a larger proportion of horizontally-infected adolescents. This stands in 
contrast to the findings of Nglazi et al and Kahana et al, that horizontally-infected youth 
are less likely to be virologically suppressed.(14, 44) However, the small numbers of 
horizontally-infected adolescents enrolled in our study meant that this unusual finding 
could not be explored further. 
 
5.2.2 Subjects with all detectable VL 
 
There were only 16 (4.9%) individuals in this study who never experienced undetectable 
VL for the duration of the follow-up period. This is markedly lower than the proportion 
reported by Nachega et al, in which 42% of adolescents never suppressed during the 
follow-up period.(8) It is also lower than that found in a vertically-infected US cohort, in 
which 24% never suppressed.(64) In our study, subjects who never experienced 
undetectable VL were similar to the rest of the study population with respect to gender 
and mode of HIV acquisition. Time on ART prior to study entry was also similar, as was 
age at start of treatment. One area where this group differed from the rest of the cohort 
was in later age of study entry; p=0.007. This may have been due to these individuals 
being identified at other services as struggling on ART, and requiring referral to a 
specialised adolescent service. Four (25%) of these had genotyped resistance to a 
protease inhibitor, suggesting that for the other 75% of subjects, poor adherence was the 







Cumulative incidence of confirmed detectable VL was 11.8 per 100 person years (PY). 
Comparison with published literature is challenging due to few studies reporting this 
outcome and methodological differences between those that do. In addition, all studies 
discussed in the literature review used a VL threshold of 1000 copies/ml, in line with 
definitions of virological failure rather than non-suppression. The most striking finding 
regarding incidence in this study was its strong association with increasing age, which will 




Our study found that 22% of the total study time was spent with a VL >100 copies/ml. A 
review of the literature revealed one other study that dealt with the duration of 
detectable VL during adolescence. Within this vertically-infected cohort of subjects aged 
7 – 30 years, 34% of total study time was spent with VL >400 copies/ml, which is higher 
than what we found in our study. The age-stratification differed from our study, and was 
divided into children aged 7 – 12 years (22% of study time with VL >400 copies/ml), 
adolescents aged 13 – 17 (30% of study time with VL >400 copies/ml) and youth aged 18 
– 30 years (44% of study time with VL >400 copies/ml). Our total study findings of 22% 
are equal to those of the lowest age group in this study even at a lower limit of detection 
of 100 copies/ml.  
 
When follow up time is restricted to the 880 PY contributed by the 159 subjects who 
experienced detectable VL, the proportion of time spent with detectable VL rises to 42%. 
This indicates that those who have detectable VL tend to remain in this state for a 
considerable proportion of their follow-up time. For adolescents, who may be sexually 
active, time spent with detectable VL should be viewed not only as time at greater risk of 
disease progression, but also time of increased risk of HIV transmission.(10, 12, 13)  
 40 
As previously indicated, duration of detectable VL is not commonly reported in the 
literature, possibly because of lack of longitudinal data. However, we believe it could be 
used as a potential marker of successful ART in adolescents. Although the duration of 
detectable VL can in part be affected by the frequency of virological testing, we believe 
that when used together with incidence and prevalence data, it has the potential to 
deepen our understanding of adherence patterns of adolescents on ART.  Moreover, 
duration of detectable VL provides important additional information that is not reflected 
in prevalence and incidence estimates. As an example, if two adolescents are followed up 
for a similar period of time and each experiences a single period of sustained detectable 
VL, each will contribute a single episode to the prevalence and incidence of the study 
population. However, one may have been unsuppressed for 5% of the follow-up time, 
and the other for 90%. These patients would be considered equal under both prevalence 
and incidence studies of non-suppression, but a treating clinician would clearly have 
more reason to be concerned about the second patient.  
 
The study outcome of duration of detectable VL thus adds important information that is 
taken into account by clinicians, but is not apparent in the literature.  
 
5.5 Re-suppression and viral rebound 
 
The longitudinal design of this study allowed us to look more closely at patterns of 
suppression and rebound detectable VL. Of the 159 subjects with detectable VL, 
approximately two thirds re-suppressed (67%). However, slightly more than one third of 
these (37%) went on to have further confirmed detectable VL. Of these, more than half 
(58%) suppressed once more, although almost a third of those left (27%) experienced 
detectable VL again. At study exit, half of the original 159 subjects with detectable VL had 
undetectable VL. Whether this pattern holds over longer periods of time or in contexts 
other than ours deserves further study. 
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The dynamic nature of adherence and detectable VL has been noted elsewhere. Childs et 
al found high rates of re-suppression after confirmed VL >400 copies/ml in a paediatric 
and adolescent cohort in the United Kingdom and Ireland. In this cohort, 69% of subjects 
had re-suppressed 24 months after rebound, comprising those who remained on the 
same regimen as well as those who switched to an alternative regimen. In the group that 
re-suppressed without regimen switch, 61% had virological rebound at most recent 
follow-up.(55) 
 
In a Thai cohort, Sudjaritruk et al found that 13% of a cohort of vertically-infected 
adolescents experienced virological rebound of >1000 copies/ml after a period of 
sustained suppression.(52) The comparatively lower rate of viral rebound could be due to 
a higher threshold for detectable VL, or to a bias towards more stable patients arising 
from the entry criterion of sustained virological suppression. 
 
In combination with the literature, our study adds to the growing body of evidence 
relating to the dynamic nature of adherence and virological outcomes. During 
adolescence, those with sustained virological suppression may become unsuppressed, 
while those with viraemia may re-suppress. Clinicians need to be alert to the fact that 
adherence behaviour may change over time, for better or worse. Further research is 




This study was primarily descriptive, and its main objectives were to examine the rate, 
duration and prevalence of detectable VL. We did, however, examine demographic data 
for associations with these outcomes. The following variables will be discussed: age, 





Our results show a clear trend of increasing rates of detectable VL as the cohort ages. The 
risk of detectable VL increased by 24% for each year from two per 100 PY at age 10 to a 
twenty-fold increase to 40 per 100 PY at 19 years of age. This is in keeping with the 
literature, in which multiple studies have found that older adolescents are at higher risk 
of detectable VL.(19, 30, 40, 57-59) Compared to those aged 10 – 12 years, adolescents 
aged 13-15 and 16 – 19 years had a double and four-fold higher risk of detectable VL 
respectively.  
 
The extremely high rates of detectable VL in the older adolescents within this cohort is of 
concern, as this occurs at the time prior to transfer to adult services where they are 
expected to be more independent. It would be useful to know whether this high risk of 
detectable VL is sustained into young adulthood, or whether this represents a peak that 




Studies exploring associations between sex, adherence and VL have mixed findings, with 
positive, negative and no associations being reported.(9, 30, 42, 44, 52) In our study sex 
was not associated with prevalence, incidence or duration of detectable VL. 
 
5.6.3 Time on ART 
 
This study found that longer time on ART was associated with decreased risk of 
detectable VL. This stands in contrast to published literature, which shows either no 
association or a decline in virological suppression with increasing time on ART. (8, 14, 40, 
62) It is not entirely clear why our findings differ from other published studies. The nature 
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of services offered by the specialised HIV adolescent clinic in which this cohort was based 
could partially account for the observation. The clinic offers a relatively well-resourced, 
adolescent-friendly service, with strong continuity of care in which each patient is 
allocated their own counsellor and physician. Subjects who had been on treatment for 
more than ten years are likely to have commenced treatment in the same clinic, and to 
have benefited from the advantages offered by this service. 
 
5.6.4 Age at ART 
 
We found that subjects who experienced detectable VL started ART later than those who 
did not; p=0.026. This is in keeping with the results of Makadzange et al, who found that 
older age of ART initiation was associated with VL >1000 copies/ml.(40) When we 
performed a similar analysis by those who initiated ART younger than 10 years compared 
to 10 years and above, we also found increased prevalence of detectable VL in the older 
group, though our findings were not significant.  
 
5.6.5 Calendar year 
 
The rate of detectable VL shows an upward trend from 2007 onward, and this rise is 
sustained until the end of the study. The reasons for this are not well understood, but we 
believe that they relate to the increasing numbers of “high risk” patients referred into the 
clinic from other services. As ART became more available in South Africa, and a 
decentralised approach was rolled out across the Cape Town metro, the Groote Schuur 
Hospital Adolescent Clinic evolved into a referral centre for adolescents with complex 
adherence problems. These adolescents are expected to be at higher risk for detectable 






The mortality rate in this study was 0.2 per 100 PY. This is identical to that reported by 
Sudjaritruk et al in a cohort of vertically-infected adolescents.(52) Our population differed 
from that in Sudjaritruk’s study which only included subjects with a history of sustained 
virological suppression, thus biasing selection towards more stable patients. The 
mortality rate in our study is considerably lower than the 1.2 per 100 PY reported by 
Nglazi et al in another South African adolescent cohort.(14) However, our study excludes 
subjects who had not spent at least 24 months on ART, so any early deaths on treatment 
would have been excluded. By including both adolescents who were already on ART 
(29%) as well as those initiating treatment, Nglazi’s study captures both early and late 
mortality.(14) 
 
In a recent cohort study, Judd et al found that the overall mortality rate for European and 
Thai children and adolescents enrolled between 1997 and 2013 was 2.5 per 100 PY in the 
first six months on ART, and 0.27 per 100 PY thereafter.(11) The mortality rate after six 
months on ART is similar to the rate in our cohort. 
 
The mortality rate in our study can thus be viewed as a late outcome on ART, and as such 
is likely to be lower than the true mortality rate for the clinic overall. However, it is in 
keeping with late outcomes reported by middle and high-income countries in Europe and 






This study has found that detectable viral load (VL) is experienced by half of adolescents, 
with a cumulative incidence of nearly 12 for every 100 adolescents in a year. Although 
other explanations exist for detectable viral load, in the context of effective antiretroviral 
therapy, this finding largely reflects poor adherence. The most concerning finding is that 
those with detectable VL spent almost half of their time in this state. This risk is further 
amplified by the fact that rates of detectable VL are higher in older adolescents who are 
more likely to be sexually active, increasing the risk of transmitting the virus.  
 
This study contributes the seldom reported phenomenon of “time spent with detectable 
VL” to the existing body of work on adolescent adherence. This is a concept that has not 
been well-explored, but may be useful in defining periods of particularly high risk of 




The findings of this study may not be generalisable to other contexts and for a number of 
reasons, the results may not be representative of HIV-infected adolescents as a whole.  
The study was based in a single centre which takes referrals of “difficult” patients from 
other services. It is possible that the study subjects experienced more challenges than 
their peers followed up in primary health care settings. 
 
Though the quality of data was generally good, the retrospective design of the study 
meant that not all the data we would have liked was readily available, in particular that 
pertaining to adherence as well as HIV genotyping. While six patients were found to have 
resistance to protease-inhibitor containing regimens, it is possible that others also 
 46 
experienced undiagnosed resistance, and ineffective ART may have been responsible for 
persistent detectable VL in their case. 
 
Inasmuch as the findings of this study are strengthened by the inclusion criterion of a 
minimum of two years’ follow-up, this also brings certain limitations. Firstly, 57 younger 
adolescents were excluded as they were younger than 12 years at the study endpoint. 
Secondly, a total of 91 subjects were excluded as they did not remain in care for long 
enough: this figure includes patients who transferred out to other services, as well as 
those who were lost to follow-up (LTFU). As a result, it is possible that the study may 
have underestimated both mortality and LTFU rates. The reported mortality and LTFU 




6.2.1 Clinical recommendations 
 
As older adolescents are at high risk of HIV viraemia, clinicians should anticipate this, and 
offer appropriate adherence support to this group. Community-based adherence support 
and group adherence counselling have shown promise in improving adolescent 
adherence to ART.(65) It is our experience that having a dedicated clinician and 
counsellor allocated to each individual helps to prevent adherence difficulties from going 
undiagnosed, while referral to a psychologist improves complex adherence problems. 
 
6.2.2 Recommendations for further study 
 
This report restricted itself to detailed descriptions of patterns of viral load and only 
minimally analysed the effect of demography and time on this pattern. There is a need to 
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analyse other risk factors that may impact on adolescent adherence to ART (such as 
mental health, orphanhood or stigmatizing medication side effects like lipoatrophy).  
 
In addition, although detectable VL is widely used as a marker of disease progression, this 
study did not report on immunological or clinical outcomes (aside from death). Data for 
making sense of these important aspects have been collected and plans are underway to 
analyse and report on these in the near future.  
 
Detectable VL rose sharply with increasing age, and was highest among 19 year olds, but 
this study did not include ages above 19. A follow up study to determine if the observed 
patterns of viraemia persist beyond 19 are warranted. There is also a need for 
independent longitudinal studies in other adolescent cohorts especially in low and 
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